Alessandra Calculli

Alessandra Calculli

Auto-generated profile, based on publicly available information

Alessandra Calculli

Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in SLEEP
Verified
Journal Article
Open access
PGPiergiorgio Grillo
Piergiorgio Grillo
DMDaniela Maftei
Daniela Maftei
ACAlessandra Calculli
Alessandra Calculli
TSTommaso Schirinzi
Tommaso Schirinzi
SMSimone Mauramati
Simone Mauramati
MTMichele Terzaghi
Michele Terzaghi
Study Objectives: PROK2 is a peptide expressed in the adult brain mediating neuroprotective functions. Previous studies reported an upregulation of prokineticin system in Parkinson’s disease (PD), but evidence in prodromal α-synucleinopathies was lacking. We investigated the expression of prokineticin-2 (PROK2) and its receptors (PKR1 and PKR2), along with oligomeric α-synuclein (oligo α-syn) as a marker of α-synuclein pathology, in olfactory neurons (ONs) from individuals with idiopathic rapid eye movement sleep behavior disorder (iRBD). Methods: Olfactory neurons, obtained by nasal brush from 28 idiopathic rapid eye movement sleep behavior disorder subjects (age: 71.2 ± 7.4 years; males: 89.3%; duration: 4.9 ± 2.5 years) and 28 healthy controls (HCs) (age:67.2 ± 11.5 years; males:64.2%), were analyzed using real-time polymerase-chain-reaction (RT-PCR), immunofluorescence (IF), and western blot (WB). In a subgroup of subjects, results were validated in serum. Results: In the idiopathic rapid eye movement sleep behavior disorder group, prokineticin-2 protein expression was reduced in both ONs (immunofluorescence: F(1,26) = 15.289, p < .001; western blot: F(1,12) = 9.073, p = .011) and serum compared with HCs (western blot: F(1,12) = 4.557, p = .050). Idiopathic rapid eye movement sleep behavior disorder subjects showed lower mRNA expression of prokineticin receptors compared with healthy controls (real-time polymerase-chain-reaction for prokineticin receptor-1: F(1,26) = 16.131, p < .001; real-time polymerase-chain-reaction for prokineticin receptor-2: F(1,39) = 4.946, p = .032). Oligo α-syn accumulation in olfactory neurons was higher in idiopathic rapid eye movement sleep behavior disorder than healthy controls, yet the difference only tended to statistical significance (immunofluorescence: F(1,18) = 3.169, p = .092). Conclusions: In contrast with findings in Parkinson’s disease, we found a downregulation of prokineticin system in idiopathic rapid eye movement sleep behavior disorder. The causes of prokineticin system downregulation in this prodromal stage may be multiple. The absence of clear oligo α-syn accumulation, known trigger of prokineticin-2, may play a role. On the other hand, a lack of activation of this system might act as predisposing factor for the development of idiopathic rapid eye movement sleep behavior disorder and, subsequently, full-blown neurodegeneration.

15 April 2026 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
ACAlessandra Calculli
Alessandra Calculli
DMDeborah Di Martino
Deborah Di Martino
PGPiergiorgio Grillo
Piergiorgio Grillo
GBGabriele Bellini
Gabriele Bellini
SGStella Gagliardi
Stella Gagliardi
MTMichele Terzaghi
Michele Terzaghi
Background: Isolated REM sleep behavior disorder (iRBD) is a prodromal stage of α-synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Evaluating trajectories of phenoconversion is crucial in this population. Plasma neurofilament light chain (NfL), a marker of axonal injury, has emerged as a promising candidate for tracking disease progression. Objectives: To assess plasma NfL levels in iRBD patients, examine their associations with clinical features, particularly neurogenic orthostatic hypotension (nOH), and explore their potential role in predicting phenoconversion. Methods: Plasma NfL was measured in 54 iRBD subjects, 54 PD, 54 healthy controls and 16 MSA. Participants underwent motor, cognitive, and non-motor symptoms assessments. Longitudinal follow-up data have been collected for iRBD subjects. NfL was quantified using the Ella platform; analyses were performed with Prism 9. Results: NfL levels were significantly higher in iRBD compared to controls and similar to PD. iRBD-nOH + patients had significantly higher NfL than nOH − counterparts, with values overlapping PD and MSA. nOH was inversely associated with hyposmia, supporting phenotypic divergence. NfL correlated positively with SCOPA-AUT and BDI scores. At follow-up, all four MSA converters had nOH at baseline. Conclusions: Plasma NfL elevation in iRBD supports its role as a marker of early neurodegeneration. Its association with nOH suggests that this autonomic feature may identify a biologically more severe iRBD phenotype, possibly on a trajectory toward MSA. These findings warrant extended longitudinal validation and support the integration of clinical and biological markers, including NfL, for stratifying conversion risk.

20 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PGPiergiorgio Grillo
Piergiorgio Grillo
DMDaniela Maftei
Daniela Maftei
ACAlessandra Calculli
Alessandra Calculli
TSTommaso Schirinzi
Tommaso Schirinzi
SMSimone Mauramati
Simone Mauramati
MTMichele Terzaghi
Michele Terzaghi
Objectives: PROK2 is a peptide expressed in the adult brain mediating neuroprotective functions. Previous studies reported an upregulation of prokineticin system in PD, but evidence in prodromal α-synucleinopathies was lacking. We investigated the expression of prokineticin-2 (PROK2) and its receptors (PKR1 and PKR2), along with oligomeric α-synuclein (oligo α-syn) as a marker of α-synuclein pathology, in olfactory neurons (ONs) from individuals with idiopathic REM sleep behavior disorder (iRBD). Methods: ONs, obtained by nasal brush from 28 iRBD subjects and 28 healthy controls (HCs), were analyzed using real-time polymerase chain reaction (RT-PCR), immunofluorescence (IF), and western blot (WB). In a subgroup of subjects, results were validated in serum samples. Results: In the iRBD group, PROK2 protein expression was reduced in both ONs (IF: F(1,26)=15.289, p<0.001; WB: F(1,12)=9.073, p=0.011) and serum compared with HCs (WB: F(1,12)=4.557, p=0.050). iRBD subjects showed lower mRNA expression of prokineticin receptors compared with HCs (RT-PCR for PKR1: F(1,26)=16.131, p<0.001; RT-PCR for PKR2: F(1,39)=4.946, p=0.032). Oligo α-syn accumulation in ONs was higher in iRBD than HCs, yet the difference only tended to statistical significance (IF: F(1,18)=3.169, p=0.092). Conclusion: In contrast with findings in PD, we found a downregulation of prokineticin system in iRBD. The causes of prokineticin system downregulation in this prodromal stage may be multiple. The absence of a clear oligo α-syn accumulation, known trigger of PROK2, may play a role. On the other hand, a lack of activation of this system might act as predisposing factor for the development of iRBD and, subsequently, full-blown neurodegeneration. Statement of significance: This study reveals a downregulation of the prokineticin system in individuals with Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD), a prodromal stage of Parkinson’s disease (PD). Prokineticin-2 (PROK2) is a peptide expressed in the adult brain mediating neuroprotective functions. In contrast to the upregulation reported in established PD, the downregulation observed in iRBD suggests a failure to activate endogenous neuroprotective mechanisms at the prodromal stage of disease, providing new insight into early processes that may predispose to neurodegeneration. Notably, the prokineticin pathway was investigated in olfactory neurons obtained through a simple, non-invasive nasal brushing, demonstrating that these cells represent an innovative and accessible source of biomarkers for central nervous system disorders.